Ziarco raises $33.1M series B
Ziarco Pharma Ltd. (Canterbury, U.K.) raised $33.1 million in a series B round led by New Enterprise Associates and Lundbeckfond Ventures. New investor Amgen Ventures and existing investors BVF Partners and Pfizer Venture Investments also participated. NEA Partner Ed Mathers and Lundbeckfond Senior Partner Johan Koerdel joined Ziarco's board, with Mathers serving as chairman.
Ziarco plans to begin in mid-2015 a Phase IIa study of ZPL-389 ( ZPL-3893787), a histamine H4 receptor (H4R4) antagonist, to treat atopic dermatitis, with data expected in mid-2016. It also hopes to start a Phase I/II study in mid-2016 of ZPL-521 ( ZPL-5212372), a topical phospholipase A2 group IVA cytosolic calcium-dependent ( PLA2G4A) inhibitor, to treat psoriasis. ...